SUNPHARMA Overzicht aandelen
Sun Pharmaceutical Industries Limited, een generiek farmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merk- en generieke formuleringen en actieve farmaceutische ingrediënten (API's) in India en daarbuiten.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 4/6 |
Sun Pharmaceutical Industries Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,808.90 |
| 52 Week Hoogtepunt | ₹1,960.35 |
| 52 Week Laag | ₹1,140.00 |
| Bèta | 0.55 |
| 11 maand verandering | -5.30% |
| 3 maanden verandering | 5.94% |
| 1 Jaar Verandering | 57.30% |
| 33 jaar verandering | 126.11% |
| 5 jaar verandering | 329.21% |
| Verandering sinds IPO | 88,881.35% |
Recent nieuws en updates
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Recent updates
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Rendement voor aandeelhouders
| SUNPHARMA | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -4.9% | 2.0% | 1.8% |
| 1Y | 57.3% | 58.6% | 36.8% |
Rendement versus industrie: SUNPHARMA underperformed the Indian Pharmaceuticals industry which returned 58.6% over the past year.
Rendement versus markt: SUNPHARMA exceeded the Indian Market which returned 36.8% over the past year.
Prijsvolatiliteit
| SUNPHARMA volatility | |
|---|---|
| SUNPHARMA Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: SUNPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatiliteit in de loop van de tijd: SUNPHARMA's weekly volatility (2%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1983 | 43,000 | Dilip Shanghvi | www.sunpharma.com |
Sun Pharmaceutical Industries Limited, een generiek farmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merk- en generieke formuleringen en actieve farmaceutische ingrediënten (API's) in India en daarbuiten. Het bedrijf biedt formuleringen in verschillende therapeutische gebieden, waaronder het centrale zenuwstelsel, dermatologie, cardiologie, oncologie, neuropsychiatrie, gastro-enterologie, anti-infectiva, diabetologie, pijn/analgetica, vitaminen/mineralen/voedingsstoffen, luchtwegen, gynaecologie, urologie, oogheelkunde, orthopedie, nefrologie, tandheelkunde en andere gebieden. Het levert API's voor medicijnen tegen kanker, peptiden, steroïden, hormonen en immunosuppressiva.
Sun Pharmaceutical Industries Limited Samenvatting
| SUNPHARMA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹4.46t |
| Inkomsten(TTM) | ₹110.54b |
| Inkomsten(TTM) | ₹503.08b |
39.3x
Koers/Winstverhouding8.6x
P/S-verhoudingIs SUNPHARMA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SUNPHARMA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹503.08b |
| Kosten van inkomsten | ₹112.67b |
| Brutowinst | ₹390.41b |
| Overige uitgaven | ₹279.87b |
| Inkomsten | ₹110.54b |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 46.07 |
| Brutomarge | 77.60% |
| Nettowinstmarge | 21.97% |
| Schuld/Eigen Vermogen Verhouding | 3.0% |
Hoe presteerde SUNPHARMA op de lange termijn?
Bekijk historische prestaties en vergelijking